These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 24337167

  • 21. Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL.
    Lee DH, Nam JK, Park SW, Lee SS, Han JY, Lee SD, Lee JW, Chung MK.
    Yonsei Med J; 2016 May; 57(3):565-71. PubMed ID: 26996553
    [Abstract] [Full Text] [Related]

  • 22. Transperineal prostate biopsy detects significant cancer in patients with elevated prostate-specific antigen (PSA) levels and previous negative transrectal biopsies.
    Dimmen M, Vlatkovic L, Hole KH, Nesland JM, Brennhovd B, Axcrona K.
    BJU Int; 2012 Jul; 110(2 Pt 2):E69-75. PubMed ID: 22093091
    [Abstract] [Full Text] [Related]

  • 23. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
    Brown LC, Ahmed HU, Faria R, El-Shater Bosaily A, Gabe R, Kaplan RS, Parmar M, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham A, Oldroyd R, Parker C, Bott S, Burns-Cox N, Dudderidge T, Ghei M, Henderson A, Persad R, Rosario DJ, Shergill I, Winkler M, Soares M, Spackman E, Sculpher M, Emberton M.
    Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
    [Abstract] [Full Text] [Related]

  • 24. Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy?
    Durkan GC, Greene DR.
    BJU Int; 1999 Jan; 83(1):34-8. PubMed ID: 10233448
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. How many cores are enough? Optimizing the transperineal prostate biopsy template.
    Schaufler C, Daigle R, Singhaviranon S, Gjertson CK, Albertsen PC, Ristau BT.
    Urol Oncol; 2022 May; 40(5):191.e1-191.e7. PubMed ID: 35067430
    [Abstract] [Full Text] [Related]

  • 29. Detection rate and factors predictive the presence of prostate cancer in patients undergoing ultrasonography-guided transperineal saturation biopsies of the prostate.
    Novara G, Boscolo-Berto R, Lamon C, Fracalanza S, Gardiman M, Artibani W, Ficarra V.
    BJU Int; 2010 May; 105(9):1242-6. PubMed ID: 19863531
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Incidence, grade and distribution of prostate cancer following transperineal template-guided mapping biopsy in patients with atypical small acinar proliferation.
    Merrick GS, Galbreath RW, Bennett A, Butler WM, Amamovich E.
    World J Urol; 2017 Jul; 35(7):1009-1013. PubMed ID: 27900453
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Metformin Does Not Predict for Prostate Cancer Diagnosis, Grade, or Volume of Disease After Transperineal Template-guided Mapping Biopsy.
    Merrick GS, Bennett A, Couture T, Butler WM, Galbreath RW, Adamovich E.
    Am J Clin Oncol; 2017 Aug; 40(4):353-357. PubMed ID: 25575041
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Clinical outcome of transrectal ultrasound-guided prostate biopsy, targeting eight cores, for detecting prostate cancer in Japanese men.
    Ishimura T, Sakai I, Hara I, Eto H, Miyake H.
    Int J Clin Oncol; 2004 Feb; 9(1):47-50. PubMed ID: 15162826
    [Abstract] [Full Text] [Related]

  • 36. Clinicopathological features of prostate cancer detected by transrectal ultrasonography-guided systematic six-sextant biopsy.
    Ito K, Ichinose Y, Kubota Y, Imai K, Yamanaka H.
    Int J Urol; 1997 Sep; 4(5):474-9. PubMed ID: 9354949
    [Abstract] [Full Text] [Related]

  • 37. [Examination for indication of systematic biopsy for diagnosis of prostate cancer].
    Muraoka K, Takahashi C, Yamamoto Y, Watanabe T, Hirakawa S, Miyagawa I.
    Nihon Hinyokika Gakkai Zasshi; 1999 Jul; 90(7):657-62. PubMed ID: 10481471
    [Abstract] [Full Text] [Related]

  • 38. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T, Discacciati A, Bergman M, Clements M, Aly M, Annerstedt M, Glaessgen A, Carlsson S, Jäderling F, Eklund M, Grönberg H, STHLM3 study group.
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The outcomes of transrectal ultrasound guided biopsy of the prostate in a New Zealand population.
    Lienert AR, Davidson PJ, Wells JE.
    N Z Med J; 2009 Jan 23; 122(1288):39-49. PubMed ID: 19182841
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.